Anaerobutyricum soehngenii as Next Generation Probiotics
A deeper understanding of the gut microbiota and its role is essential for future healthcare strategies. In this regard, extensive study of the potential use of selected probiotic bacteria species and their strains is desperately needed for the prevention and treatment of numerous human and animal diseases. At Creative Biolabs, we team up with you to understand your needs. Our experienced R&D team provides you with the support you need during live biotherapeutic products (LBP) development.
Introduction of Anaerobutyricum soehngenii (A. soehngenii)
A. soehngenii is an anaerobic Gram-positive, catalase-negative bacterium belonging to the clostridial cluster XIVa of the phylum Firmicutes. A. soehngenii has bile acid sodium transporter and choloylglycine hydrolase genes, so it can affect the host bile acid metabolism. It can produce both propionate and butyrate, metabolites that have been shown to have a positive effect on gut and overall health. The type strain, L2-7T (=DSM 17630T=KCTC 15707T), was isolated from human infant faeces. The DNA G+C content of the type strain is 38.6 mol%.
A. soehngenii for Disease Treatment
The potential next-generation probiotics with good prospects for improving T2DM have attracted increasing attention, such as Akkermansia muciniphila, A. soehngenii and Parabacteroides distasonis. The beneficial effects of these next-generation probiotics include improving insulin sensitivity, reducing inflammation and weight gain, and improving glucose homeostasis by producing short-chain fatty acids or secondary bile acids. In addition, oral treatment with A. soehngenii species had a modest blood pressure lowering effect in humans.
In a db/db mouse model, live cells of A. soehngenii L2-7T were found to increase insulin sensitivity and affect intestinal and liver gene expression. A recent study showed that a single duodenal administration of A. soehngenii L2-7T affected gene expression in the duodenum, stimulated the secretion of GLP-1, and improved insulin sensitivity. These results altogether showed that A. soehngenii L2-7T had great potential to serve as a next-generation therapeutic product for people that are at risk of developing type 2 diabetes and showed increased levels of insulin resistance.
Fig.1 Causal relationship between A. soehngenii and obesity. (Li,2021)
What Services Can We Provide for A. soehngenii at Creative Biolabs?
A. soehngenii Related Products at Creative Biolabs
We supply a variety of A. soehngenii strains of different preservation numbers as below. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
A. soehngenii plays an important role in metabolic syndrome disease and can be developed as promising potential therapeutic probiotics. If you are interested in our A. soehngenii related services or products, Creative Biolabs is happy to discuss with you and determine the most effective solution for you. Please feel free to contact us for further information.
Reference
-
Li, L.; et al. The gut microbiota and its products: Establishing causal relationships with obesity related outcomes. Obes Rev. 2021, 22: e13341.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
